Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Section 4 of 6

Clinical evidence

467 evidence topics · 59 sources

Study summaries

Launch-HTN

Objective
Location and study date
Study locations by country in the ClinicalTrials.gov record
CountryLocations listed in the record
United States“Alabama Locations”; “Arizona Locations”; “California Locations”; “Connecticut Locations”; “Florida Locations”; “Georgia Locations”; “Idaho Locations”; “Illinois Locations”; “Indiana Locations”; “Kentucky Locations”; “Louisiana Locations”; “Massachusetts Locations”; “Mississippi Locations”; “Missouri Locations”; “Nebraska Locations”; “Nevada Locations”; “New York Locations”; “North Carolina Locations”; “Ohio Locations”; “Oklahoma Locations”; “Pennsylvania Locations”; “Tennessee Locations”; “Texas Locations”; “Utah Locations”; “Virginia Locations”
Australia“Heidelberg Heights, Australia”; “St Albans, Australia”; “Castle Hill, New South Wales, Australia”; “Gosford, New South Wales, Australia”; “Waratah, New South Wales, Australia”; “Sippy Downs, Queensland, Australia”; “Southport, Queensland, Australia”; “Taringa, Queensland, Australia”; “Adelaide, South Australia, Australia”; “Hobart, Tasmania, Australia”; “Perth, Western Australia, Australia”
Bulgaria“Gabrovo, Bulgaria”; “Pleven, Bulgaria”; “Sofia, Bulgaria”; “Stara Zagora, Bulgaria”; “Veliko Tarnovo, Bulgaria”
Canada“Edmonton, Alberta, Canada”; “East York, Ontario, Canada”; “Montreal, Quebec, Canada”
France“Annecy, France”; “Bordeaux, France”; “Nîmes, France”; “Saint-Priest-en-Jarez, France”; “Strasbourg, France”
Germany“Berlin, Germany”; “Deggingen, Germany”; “Karlsruhe, Germany”; “Leipzig, Germany”; “Wiesbaden, Germany”; “Hanover, Lower Saxony, Germany”; “Mainz, Rhineland-Palatinate, Germany”; “Dresden, Saxony, Germany”; “Leipzig, Saxony, Germany”
Italy“Ancona, Italy”; “Bologna, Italy”; “Brescia, Italy”; “Ferrara, Italy”; “Genova, Italy”; “L’Aquila, Italy”; “Messina, Italy”; “Milan, Italy”; “Modena, Italy”; “Naples, Italy”; “Pavia, Italy”; “Pisa, Italy”; “Rome, Italy”; “Rozzano, Milan, Italy”; “Roma, Rome, Italy”
Netherlands“Utrecht, Netherlands”; “Nijmegen, Gelderland, Netherlands”; “Amsterdam, North Holland, Netherlands”; “Dordrecht, South Holland, Netherlands”
Poland“Katowice, Poland”; “Lodz, Poland”; “Olsztyn, Poland”; “Krakow, Lesser Poland Voivodeship, Poland”; “Lubin, Polska, Poland”; “Skierniewice, Polska, Poland”; “Warsaw, Polska, Poland”; “Olsztyn, Warmian-Masurian Voivodeship, Poland”
Puerto Rico“San Juan, Puerto Rico”
Romania“Brasov, Romania”; “Bucharest, Romania”; “Cluj-Napoca, Romania”; “Craiova, Romania”; “Oradea, Romania”; “Timișoara, Romania”; “Târgu Mureş, Mureș County, Romania”; “Timișoara, Timiș County, Romania”
Spain“Badajoz, Spain”; “Barcelona, Spain”; “Córdoba, Spain”; “Granada, Spain”; “Madrid, Spain”; “Santiago de Compostela, Spain”; “Valencia, Spain”
United Kingdom“Aberdeen, United Kingdom”; “Birmingham, United Kingdom”; “Canterbury, United Kingdom”; “Carshalton, United Kingdom”; “Chippenham, United Kingdom”; “Glasgow, United Kingdom”; “Newquay, United Kingdom”; “Sheffield, United Kingdom”; “Stockton-on-Tees, United Kingdom”; “Fowey, Great Britain, United Kingdom”; “London, Great Britain, United Kingdom”; “Plymouth, Great Britain, United Kingdom”; “Torpoint, Great Britain, United Kingdom”; “Canterbury, Kent, United Kingdom”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Blood pressure in the FDA table of surrogate endpoints
Disease or usePatient populationSurrogate endpointType of approval appropriate for
“Hypertension”“Patients with hypertension”“Blood pressure”“Traditional”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics by randomized group
CharacteristicLorundrostat 50 mg then 100 mg (n = 270)Lorundrostat 50 mg (n = 541)Placebo (n = 272)
Age, mean (SD), y“61.4 (10.3)”View highlighted excerpt for this quote“61.7 (10.6)”View highlighted excerpt for this quote“61.8 (10.4)”View highlighted excerpt for this quote
Male, No. (%)“142 (52.6)”View highlighted excerpt for this quote“294 (54.3)”View highlighted excerpt for this quote“139 (51.1)”View highlighted excerpt for this quote
Female, No. (%)“128 (47.4)”View highlighted excerpt for this quote“247 (45.7)”View highlighted excerpt for this quote“133 (48.9)”View highlighted excerpt for this quote
Asian, No. (%) (lorundrostat n = 267 and n = 535)“4 (1.5)”View highlighted excerpt for this quote“14 (2.6)”View highlighted excerpt for this quote“6 (2.2)”View highlighted excerpt for this quote
Black or African American, No. (%) (lorundrostat n = 267 and n = 535)“72 (26.7)”View highlighted excerpt for this quote“152 (28.1)”View highlighted excerpt for this quote“87 (32.0)”View highlighted excerpt for this quote
White, No. (%) (lorundrostat n = 267 and n = 535)“190 (70.4)”View highlighted excerpt for this quote“366 (67.7)”View highlighted excerpt for this quote“177 (65.1)”View highlighted excerpt for this quote
Hispanic or Latino ethnicity, No. (%)“102 (37.8)”View highlighted excerpt for this quote“191 (35.3)”View highlighted excerpt for this quote“101 (37.1)”View highlighted excerpt for this quote
Body mass index, mean (SD)“32.8 (6.7)”View highlighted excerpt for this quote“33.0 (6.9)”View highlighted excerpt for this quote“32.6 (7.4)”View highlighted excerpt for this quote
Body mass index ≥30 (obesity), No. (%)“166 (61.5)”View highlighted excerpt for this quote“351 (64.9)”View highlighted excerpt for this quote“168 (61.8)”View highlighted excerpt for this quote
eGFR at randomization, mean (SD), mL/min/1.73 m2“92.8 (17.6)”View highlighted excerpt for this quote“90.1 (17.8)”View highlighted excerpt for this quote“91.2 (16.4)”View highlighted excerpt for this quote
eGFR ≥60 mL/min/1.73 m2, No. (%)“255 (94.4)”View highlighted excerpt for this quote“500 (92.9)”View highlighted excerpt for this quote“260 (96.3)”View highlighted excerpt for this quote
Diabetes, No. (%)“76 (28.2)”View highlighted excerpt for this quote“173 (32.2)”View highlighted excerpt for this quote“89 (33.0)”View highlighted excerpt for this quote
Taking 2 antihypertensive medications, No. (%)“106 (39.3)”View highlighted excerpt for this quote“213 (39.4)”View highlighted excerpt for this quote“113 (41.5)”View highlighted excerpt for this quote
Taking ≥3 antihypertensive medications, No. (%)“164 (60.7)”View highlighted excerpt for this quote“328 (60.6)”View highlighted excerpt for this quote“159 (58.5)”View highlighted excerpt for this quote
Thiazide or thiazide-like diuretic, No. (%)“259 (95.9)”View highlighted excerpt for this quote“520 (96.1)”View highlighted excerpt for this quote“259 (95.2)”View highlighted excerpt for this quote
ACE inhibitor or ARB, No. (%)“237 (87.8)”View highlighted excerpt for this quote“467 (86.3)”View highlighted excerpt for this quote“225 (82.7)”View highlighted excerpt for this quote
Calcium channel blocker, No. (%)“140 (51.9)”View highlighted excerpt for this quote“278 (51.4)”View highlighted excerpt for this quote“135 (49.6)”View highlighted excerpt for this quote
Glucagon-like peptide-1 receptor agonists, No. (%)“13 (4.8)”View highlighted excerpt for this quote“30 (5.6)”View highlighted excerpt for this quote“9 (3.3)”View highlighted excerpt for this quote
Sodium-glucose cotransporter 2 inhibitors, No. (%)“14 (5.2)”View highlighted excerpt for this quote“21 (3.9)”View highlighted excerpt for this quote“13 (4.8)”View highlighted excerpt for this quote
Systolic blood pressure, mean (SD), mm Hg“146.6 (11.1)”View highlighted excerpt for this quote“149.0 (12.2)”View highlighted excerpt for this quote“148.8 (12.2)”View highlighted excerpt for this quote
Systolic blood pressure <140 mm Hg, No. (%)“83 (30.7)”View highlighted excerpt for this quote“137 (25.3)”View highlighted excerpt for this quote“73 (26.8)”View highlighted excerpt for this quote
Systolic blood pressure 140 to <160 mm Hg, No. (%)“152 (56.3)”View highlighted excerpt for this quote“294 (54.3)”View highlighted excerpt for this quote“144 (52.9)”View highlighted excerpt for this quote
Systolic blood pressure ≥160 mm Hg, No. (%)“35 (13.0)”View highlighted excerpt for this quote“110 (20.3)”View highlighted excerpt for this quote“55 (20.2)”View highlighted excerpt for this quote
Diastolic blood pressure, mean (SD), mm Hg“86.3 (9.2)”View highlighted excerpt for this quote“87.8 (9.0)”View highlighted excerpt for this quote“87.1 (9.1)”View highlighted excerpt for this quote
Efficacy results
Primary, secondary, and prespecified exploratory blood pressure outcomes
OutcomeLorundrostat baseline, mean (SD)Lorundrostat follow-up, mean (SD)Lorundrostat least-squares mean change (95% CI)Placebo baseline, mean (SD)Placebo follow-up, mean (SD)Placebo least-squares mean change (95% CI)Least-squares mean difference (95% CI)P value
Primary: systolic BP, baseline to 6 wk (pooled lorundrostat n = 808; placebo n = 270)“148.2 (11.9)”View highlighted excerpt for this quote“133.6 (15.3)”View highlighted excerpt for this quote“−16.9 (−19.0 to −14.9)”View highlighted excerpt for this quote“148.6 (12.1)”View highlighted excerpt for this quote“140.7 (15.0)”View highlighted excerpt for this quote“−7.9 (−11.5 to −4.2)”View highlighted excerpt for this quote“−9.1 (−13.3 to −4.9)”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Secondary: systolic BP <130 mm Hg at 6 wk, No. (%); difference as odds ratio (95% CI)“20 (2.5)”View highlighted excerpt for this quote“356 (44.1)”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“65 (24.1)”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“3.4 (1.5 to 7.8)”View highlighted excerpt for this quote“.003”View highlighted excerpt for this quote
Secondary: taking 2 antihypertensive drugs, 6 wk (lorundrostat n = 318; placebo n = 112; 97.5% CI where reported)“147.6 (11.5)”View highlighted excerpt for this quote“134.2 (14.9)”View highlighted excerpt for this quote“−16.1 (−19.1 to −13.0)”View highlighted excerpt for this quote“148.0 (11.3)”View highlighted excerpt for this quote“141.4 (14.4)”View highlighted excerpt for this quote“−7.2 (−11.7 to −2.8)”View highlighted excerpt for this quote“−8.8 (−14.8 to −2.9)”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Secondary: taking ≥3 antihypertensive drugs, 6 wk (lorundrostat n = 490; placebo n = 158; 97.5% CI)“148.6 (12.1)”View highlighted excerpt for this quote“133.2 (15.6)”View highlighted excerpt for this quote“−17.2 (−19.6 to −14.7)”View highlighted excerpt for this quote“149.0 (12.6)”View highlighted excerpt for this quote“140.4 (15.5)”View highlighted excerpt for this quote“−8.1 (−12.4 to −3.8)”View highlighted excerpt for this quote“−9.0 (−14.0 to −4.1)”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Secondary: systolic BP, baseline to 12 wk, escalated dose group (lorundrostat n = 270)“146.6 (11.1)”View highlighted excerpt for this quote“131.9 (14.3)”View highlighted excerpt for this quote“−15.7 (−19.3 to −12.2)”View highlighted excerpt for this quote“148.6 (12.1)”View highlighted excerpt for this quote“141.2 (15.4)”View highlighted excerpt for this quote“−7.3 (−11.1 to −3.5)”View highlighted excerpt for this quote“−8.4 (−13.6 to −3.2)”View highlighted excerpt for this quote“.002”View highlighted excerpt for this quote
Secondary: within-participant analysis, 12 wk (n = 92; 97.5% CI)“148.3 (12.4)”View highlighted excerpt for this quote“138.1 (14.8)”View highlighted excerpt for this quote“−10.2 (−14.3 to −6.1)”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Exploratory: diastolic BP, baseline to 6 wk“87.3 (9.1)”View highlighted excerpt for this quote“79.9 (10.4)”View highlighted excerpt for this quote“−8.6 (−9.9 to −7.3)”View highlighted excerpt for this quote“87.1 (9.0)”View highlighted excerpt for this quote“83.2 (10.1)”View highlighted excerpt for this quote“−5.2 (−7.4 to −3.0)”View highlighted excerpt for this quote“−3.4 (−5.9 to −0.8)”View highlighted excerpt for this quote“.01”View highlighted excerpt for this quote
Exploratory: systolic BP, baseline to 12 wk, 50 mg group (lorundrostat n = 538)“149.1 (12.2)”View highlighted excerpt for this quote“132.5 (16.0)”View highlighted excerpt for this quote“−19.0 (−21.6 to −16.3)”View highlighted excerpt for this quote“148.6 (12.1)”View highlighted excerpt for this quote“141.2 (15.4)”View highlighted excerpt for this quote“−7.3 (−11.1 to −3.5)”View highlighted excerpt for this quote“−11.6 (−16.3 to −7.0)”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Sensitivity analyses of the primary endpoint
AnalysisLorundrostat LS mean (SE)Placebo LS mean (SE)LS mean difference (SE)95% CI of LS mean differenceP value
Sensitivity analysis 1: intercurrent events treated as missing at random (lorundrostat n = 808; placebo n = 270)“-16.9 (1.1)”“-7.9 (1.9)”“-9.1 (2.1)”“-13.3 to -4.9”“<0.001”
Sensitivity analysis 2: all missing data treated as missing not at random (lorundrostat n = 808; placebo n = 270)“-16.5 (1.1)”“-7.9 (1.9)”“-8.6 (2.2)”“-12.2 to -4.4”“<0.001”
Sensitivity analysis 4: observed data only (lorundrostat n = 755; placebo n = 257)“-17.0 (1.1)”“-7.9 (1.9)”“-9.1 (2.1)”“-13.3 to -4.9”“<0.001”
Participants with and without chronic kidney disease: results by stage
CKD stage (placebo N; lorundrostat 50 mg N)Placebo AOSBP LSM (95% CI) change at week 12Lorundrostat 50 mg AOSBP LSM (95% CI) change at week 12Placebo adjusted (95% CI)Placebo week 12 % with AOSBP <130 mmHgLorundrostat 50 mg week 12 % with AOSBP <130 mmHg
No CKD (202; 406)“-7.2 (-11.3, -3.2)”“-19.4 (-22.2, -16.6)”“-12.2 (-17.1, -7.3)”“22.1”“48.0”
Stage 1 (30; 58)“-8.9 (-15.4, -2.3)”“-19.5 (-24.1, -14.9)”“-10.6 (-18.6, -2.6)”“18.4”“50.6”
Stage 2 (25; 31)“-9.1 (-15.9, -2.4)”“-16.7 (-22.6, -10.8)”“-7.6 (-16.5, 1.4)”“12.0”“28.4”
Stage 3 (10; 38)“-8.5 (-18.1, 1.1)”“-18.5 (-24.1, -13.0)”“-10.1 (-21.1, 1.0)”“30.0”“47.0”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events by randomized group
Event, No. (%)Lorundrostat 50 mg then 100 mg (n = 270)Lorundrostat 50 mg (n = 538)Placebo (n = 270)
Died“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (0.4)”View highlighted excerpt for this quote
Serious adverse event“2 (0.7)”View highlighted excerpt for this quote“12 (2.2)”View highlighted excerpt for this quote“8 (3.0)”View highlighted excerpt for this quote
Treatment-emergent adverse event, severe“6 (2.2)”View highlighted excerpt for this quote“9 (1.7)”View highlighted excerpt for this quote“8 (3.0)”View highlighted excerpt for this quote
Treatment-emergent adverse event, moderate“30 (11.1)”View highlighted excerpt for this quote“100 (18.6)”View highlighted excerpt for this quote“31 (11.5)”View highlighted excerpt for this quote
Treatment-emergent adverse event, mild“115 (42.6)”View highlighted excerpt for this quote“180 (33.5)”View highlighted excerpt for this quote“59 (21.9)”View highlighted excerpt for this quote
Special interest: severely elevated blood pressure“2 (0.7)”View highlighted excerpt for this quote“10 (1.9)”View highlighted excerpt for this quote“11 (4.1)”View highlighted excerpt for this quote
Special interest: hypotension with symptoms“5 (1.9)”View highlighted excerpt for this quote“11 (2.0)”View highlighted excerpt for this quote“1 (0.4)”View highlighted excerpt for this quote
Special interest: hyperkalemia“7 (2.6)”View highlighted excerpt for this quote“11 (2.0)”View highlighted excerpt for this quote“1 (0.4)”View highlighted excerpt for this quote
Special interest: hyponatremia“28 (10.4)”View highlighted excerpt for this quote“37 (6.9)”View highlighted excerpt for this quote“9 (3.3)”View highlighted excerpt for this quote
Special interest: glucocorticoid deficiency“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (1.1)”View highlighted excerpt for this quote
Special interest: reduction in estimated glomerular filtration rate“9 (3.3)”View highlighted excerpt for this quote“16 (3.0)”View highlighted excerpt for this quote“2 (0.7)”View highlighted excerpt for this quote
Serum sodium and potassium thresholds by randomized group
Level, n (%)Lorundrostat 50 to 100 mg daily (n=270)Lorundrostat 50 mg (n=538)Placebo (n=270)
Serum sodium <132 mmol/L“22 (8.1)”“38 (7.1)”“13 (4.8)”
Serum sodium <130 mmol/L“11 (4.1)”“14 (2.6)”“4 (1.5)”
Serum sodium <125 mmol/L“4 (1.5)”“4 (0.7)”“1 (0.4)”
Serum potassium 5.6 to 6.0 mmol/L, single value“29 (10.7)”“38 (7.1)”“3 (1.1)”
Serum potassium 6.1 to 6.5 mmol/L, single value“2 (0.7)”“5 (0.9)”“1 (0.4)”
Serum potassium >6.5 mmol/L, single value“2 (0.7)”“1 (0.2)”“1 (0.4)”
Serum potassium 5.6 to 6.0 mmol/L, confirmed“24 (8.9)”“31 (5.8)”“2 (0.7)”
Serum potassium 6.1 to 6.5 mmol/L, confirmed“2 (0.7)”“3 (0.6)”“1 (0.4)”
Serum potassium >6.5 mmol/L, confirmed“1 (0.4)”“0”“0”
Study limitations
Summary: study limitations

Launch-HTN randomized 1,083 participants and compared lorundrostat with placebo for 12 weeks, a duration the investigators describe as “consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration”. Longer-term data come from the open-label extension, which enrolled 632 of the 808 participants who received lorundrostat in Launch-HTN. The trial had no active comparator. The primary endpoint, unattended automated office systolic blood pressure at week 6, was chosen “to reflect usual clinical practice”; the investigators note that ambulatory measurement “is the gold standard for assessment of BP”. FDA guidance attributes the cardiovascular benefits of antihypertensive drugs largely to the decrease in blood pressure, and the trial did not measure cardiovascular outcomes.

In the escalation group, 92 of 270 participants (34.1%) met the week 6 criteria and received 100 mg, and the investigators conclude that the higher dose “provided no additional benefit” to participants who had not reached goal on 50 mg; the week 12 placebo-adjusted difference in the escalation group (−8.4 mm Hg) was smaller than in the 50 mg group (−11.6 mm Hg). Two week 12 values are reported for the 50 mg group: −11.6 mm Hg in the publication and 11.7 mm Hg in the March 2025 topline announcement.

Eligibility excluded people with eGFR below 45 mL/min/1.73 m2, serum potassium above 5.0 mmol/L at screening or above 4.8 mmol/L at randomization, serum sodium below 135 mmol/L, or heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months, and prohibited mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, and potassium-sparing diuretics. Of the 1,083 participants, 685 (63.3%) had obesity and 432 (39.9%) were taking 2 antihypertensive medications, so the population includes people who would not meet the 2025 AHA/ACC definition of resistant hypertension. Three participants were randomized in Canada. The publication reports 159 sites in 13 countries, while the registry lists 184 locations. Hyperkalemia rates depend on the definition: a single serum potassium above 6.0 mmol/L occurred in 1.5% and 1.1% of the two lorundrostat groups and 0.7% of the placebo group, while the company reports confirmed hyperkalemia of 1.1% and 0.6%, respectively. The responder analysis is described as a “secondary analysis” and the chronic kidney disease analysis as a “Post hoc analysis”; both are published as conference abstracts. No health-related quality of life or patient-reported outcome was reported. The sponsor's chief medical officer and lead statistician are listed among the sponsor leadership of the trial and are authors of the publication.

Advance-HTN

Objective
Location and study date
Study design
Trial periods and their durations in the trial presentation
PeriodQuoted record
Screening“2 weeks”
Single-blind run-in on the standardized regimen“3 weeks”
Randomized double-blind treatment“12 weeks”
After the end of treatment“Open-label extension”; “2-week end of study visit”; “4-week washout”
Eligibility criteria
Blood pressure, medication, and laboratory thresholds in the trial presentation
CriterionQuoted record
Background antihypertensive medications at screening“2 - 5 BP medications”
Office blood pressure at screening“SBP 140 to 180 mm Hg, or DBP 90 to 110 mm Hg”
24-hour ambulatory blood pressure before randomization“SBP 130 to 180 mm Hg, or DBP > 80 mm Hg”
Serum sodium“Na+ ≥ 135”
Estimated glomerular filtration rate“eGFR ≥ 45”
Treatment
Study outcomes
Rationale for using change in 24-hour ambulatory systolic blood pressure as the primary endpoint
Registered secondary outcome measures in the ClinicalTrials.gov record
Outcome measureTime frame
“Change from baseline in 24-hour average ABPM SBP at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo”“Baseline to Week 4”
“Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo”“at Week 4”
“Change from baseline in 24-hour average ABPM SBP at Week 4 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo”“Baseline to Week 4”
“Change from baseline in automated office BP (AOBP) SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at Week 4 (within-subjects analysis)”“Baseline to Week 12”
“Change from baseline in 24-hour average ABPM SBP at Week 4, by number of AHT medications in the standardized AHT regimen (2 and 3) in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo”“Baseline to Week 4”
“Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 12 in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo”“Baseline to Week 12”
“Change from baseline in 24-hour average ABPM SBP at Week 12 by obesity status in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo”“Baseline to Week 12”
“Change from baseline in daytime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo”“Baseline to Week 4 and Week 12”
“Change from baseline in AOBP SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo”“Baseline to Week 4 and Week 12”
“Change from baseline in nighttime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo”“Baseline to Week 4 and Week 12”
“Change from baseline in 24-hour average ABPM SBP at Week 12, in subjects randomized to lorundrostat (pooled dosages) compared to subjects randomized to placebo”“Baseline to Week 12”
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and statistical power

No evidence found.

Description of analysis sets
Results
Participant disposition
Baseline characteristics
Participant characteristics by treatment group in the trial presentation
CharacteristicPlaceboLorundrostat 50 mgLorundrostat 50 to 100 mg
Age (years)“59”“61”“61”
Women (%)“35%”“40%”“44%”
Black or African-American (%)“46%”“53%”“58%”
BMI (kg/m2)“32”“31”“32”
eGFR (randomization)“74”“77”“76”
Office BP (screening)“155/91”“153/88”“152/89”
24-hour ABPM (randomization)“141/87”“141/86”“141/87”
Efficacy results
Key secondary end point: 24-hour average systolic blood pressure below 125 mm Hg at week 4
GroupProportion with 24-hour average SBP <125 mm Hg at week 4
Placebo“18%”
Lorundrostat 50 mg (all)“41%”
Odds ratio (95% CI)“3.3 (1.4 to 7.8) P < 0.001”
Key secondary end point: change at week 4 by number of background medications
Background medicationsPlacebo nPlacebo change (mm Hg)Lorundrostat nLorundrostat change (mm Hg)Placebo-adjusted difference
2“n = 60”“-5.1”“n = 117”“-11.2”“-6.1 (-10.8 to -1.4) P = 0.001”
3“n = 34”“-7.2”“n = 71”“-11.8”“-4.6 (-10.6 to 1.5) P = 0.060”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events by treatment group in the trial presentation
Adverse eventPlaceboLorundrostat 50 mgLorundrostat 50 to 100 mg
Any serious AE“2%”“6%”“8%”
Any study-drug related serious AE“0”“2%”“1%”
Hypotension“3%”“9%”“8%”
Hyponatremia“6%”“9%”“11%”
Hyperkalemia (>6.0 mmol/L), single value“0”“5%”“7%”
Hyperkalemia (>6.0 mmol/L), confirmed via per protocol repeat testing“0”“2%”“3%”
Study limitations
Summary

Advance-HTN was a 12-week phase 2 trial (the presentation calls it a “Phase 2b trial”) in 285 randomized participants at sites in the United States only (104 locations in the registry record; 103 sites in the presentation). Every participant was switched to a standardized regimen of a diuretic, olmesartan, and, for those previously on 3 to 5 drugs, amlodipine, so the results describe lorundrostat added to that regimen and may differ from its effect on top of usual background therapy; the presenters list the need for “additional data using office blood pressure on top of usual care” from Launch-HTN as a limitation. Of 926 participants who started the standardized regimen, 641 were ineligible for randomization (53% because of the ambulatory blood pressure criterion), which selects a population with confirmed uncontrolled hypertension on a standardized regimen.

The 50 to 100 mg dose-adjustment strategy produced a smaller placebo-adjusted reduction at week 12 (-6.5 mm Hg) than the stable 50 mg dose (-7.9 mm Hg), and 19 participants were escalated to 100 mg, so the trial gives limited information on the 100 mg dose. The week 4 subgroup on 3 background medications (71 lorundrostat and 34 placebo participants) had a placebo-adjusted difference of -4.6 mm Hg with a confidence interval that crossed zero (P = 0.060). The placebo group had a 24-hour systolic reduction of 7.4 mm Hg at week 12.

Single-value potassium above 6.0 mmol/L occurred in 5.3% and 7.4% of the two lorundrostat groups (2.1% and 3.2% after confirmation by repeat testing). The trial was “Not head-to-head with other classes of antihypertensive medications” and “Not a cardiovascular or kidney outcome trial”. As of November 2026 no posted results were located in the registry record, and participant disposition after randomization, discontinuations for adverse events, mean changes in potassium, sodium, and eGFR, and daytime, nighttime, and office blood pressure results by arm are not reported in the publication abstract, the presentation, the registry record, or the company releases.

Transform-HTN

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“Non-Randomized”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Phase“Phase 3”
Enrollment“1076”
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size

No evidence found.

Number randomized in the randomized treatment withdrawal substudy

No evidence found.

Description of analysis sets
Results
Participant disposition
Participants enrolled from Advance-HTN and Explore-CKD

No evidence found.

Baseline characteristics
Baseline characteristics of the Launch-HTN cohort (safety population)
CharacteristicLorundrostat (N=632)
Age, mean ±SD, years“61.2 ± 10.5”
Female, n (%)“292 (46.2)”
Black or African American, n (%)“155 (24.5)”
Hispanic or Latino, n (%)“248 (39.2)”
BMI ≥30 kg/m2, n (%)“395 (62.5)”
eGFR, mean ±SD, mL/min/1.73 m2“92.7 ± 17.4”
Office SBP, mean ±SD, mmHg“148.5 ± 11.9”
2 antihypertensive drugs, n (%)“262 (41.5)”
3 or more antihypertensive drugs, n (%)“370 (58.5)”
Thiazide or thiazide-like diuretic, n (%)“601 (95.1)”
ACE inhibitor or ARB, n (%)“546 (86.4)”
Calcium channel blocker, n (%)“295 (46.7)”
Beta blockers, n (%)“209 (33.1)”
Efficacy results
Renin-angiotensin-aldosterone system biomarkers at week 48 (not prespecified)
BiomarkerPercent change in geometric mean from baseline at week 48
Serum aldosterone“-54.8%”
Plasma renin activity“+123.9%”
Aldosterone-renin ratio“-79.8%”
Randomized treatment withdrawal substudy: change in automated office systolic blood pressure from week 12 to week 16

No evidence found.

Efficacy in participants enrolled from Advance-HTN and Explore-CKD

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events during the 36-week open-label period
Participants, n (%)Lorundrostat (N=632)
Any treatment-emergent adverse event“413 (65.3)”
Moderate intensity“141 (22.3)”
Severe intensity“20 (3.2)”
Treatment-emergent adverse event leading to study drug withdrawal“37 (5.9)”
Hyperkalemia leading to study drug withdrawal“10 (1.6)”
Any serious adverse event“27 (4.3)”
Death“0”
Treatment-related serious treatment-emergent adverse event (investigator determined)“2 (0.3)”
Hyperkalemia requiring trial drug modification (adverse event of special interest)“32 (5.1)”
Hyponatremia requiring trial drug modification (adverse event of special interest)“28 (4.4)”
Hypotension with symptoms (adverse event of special interest)“13 (2.1)”
Serum potassium >6.0 mmol/L, confirmed per protocol repeat testing“16 (2.5)”
Study limitations
Summary

Transform-HTN is a phase 3, single-group, open-label extension registered with 1,076 participants from three parent studies (Launch-HTN, Advance-HTN, and Explore-CKD). The only results available as of November 2026 are for the Launch-HTN cohort, presented as congress slides and a company press release on November 8, 2026; no peer-reviewed publication and no posted registry results were located, and the record lists a certification or extension request for results submission first submitted on July 15, 2026. Of 808 participants who received lorundrostat in Launch-HTN, 632 (78%) enrolled, so the cohort is limited to participants who completed the parent trial and chose to continue, which may favor participants who tolerated and responded to treatment. The primary endpoint is a within-group change from the Launch-HTN baseline, which includes the 12-week double-blind period; after the 12-week double-blind period there was no concurrent control group except during the 4-week withdrawal substudy, and in Launch-HTN the placebo group's automated office systolic blood pressure fell by 7.9 mm Hg at week 6, so the 17.8 mmHg change at week 48 cannot be attributed entirely to lorundrostat. The efficacy analysis (504 participants) excluded participants randomized to placebo in the withdrawal substudy, whereas the safety analysis included all 632; missing week 48 values were imputed with a shift factor based on the parent trial's placebo group. The randomized treatment withdrawal substudy, the only randomized comparison in the trial, is a registered primary outcome (change in automated office systolic blood pressure from extension week 12 to week 16) and is listed as completed, but neither its sample size nor its results were located in any public document. Only the office systolic blood pressure change and the proportion below 130 mmHg were prespecified; the biomarker results were not. Serum creatinine was measured by an enzymatic assay in Launch-HTN and a Jaffe assay in the extension, which limits comparison of eGFR across the two periods. No quality-of-life or patient-reported outcome was reported, and no results were located for participants who entered from Advance-HTN or Explore-CKD.

Target-HTN

Objective
Location and study date
Registered locations and study dates
FieldQuoted record
Study start (actual)“2021-07-01”
Primary completion (actual)“2022-09-07”
Study completion (actual)“2022-10-07”
Other study ID number“MLS-101-201”
Sponsor“Mineralys Therapeutics Inc.”
Study design
Registered design details
FieldQuoted record
Phase“Phase 2”
Allocation“Randomized”
Interventional model“Parallel Assignment”
Masking“Quadruple”
Primary purpose“Treatment”
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in office systolic blood pressure as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
FieldQuoted record
Enrollment (actual)“200”
Participants randomized and analyzed for the primary endpoint by group
GroupRandomized (baseline table)Primary end point analysis (efficacy table)
Cohort 1, lorundrostat 100 mg once daily“100 mg once daily (n = 30)”View highlighted excerpt for this quote“100 mg once daily (n = 25)”View highlighted excerpt for this quote
Cohort 1, lorundrostat 50 mg once daily“50 mg once daily (n = 28)”View highlighted excerpt for this quote“50 mg once daily (n = 28)”View highlighted excerpt for this quote
Cohort 1, lorundrostat 25 mg twice daily“25 mg twice daily (n = 30)”View highlighted excerpt for this quote“25 mg twice daily (n = 28)”View highlighted excerpt for this quote
Cohort 1, lorundrostat 12.5 mg twice daily“12.5 mg twice daily (n = 22)”View highlighted excerpt for this quote“12.5 mg twice daily (n = 19)”View highlighted excerpt for this quote
Cohort 1, lorundrostat 12.5 mg once daily“12.5 mg once daily (n = 23)”View highlighted excerpt for this quote“12.5 mg once daily (n = 19)”View highlighted excerpt for this quote
Cohort 1, placebo“Placebo (n = 30)”View highlighted excerpt for this quote“Placebo (n = 29)”View highlighted excerpt for this quote
Cohort 2, lorundrostat 100 mg once daily“Lorundrostat, 100 mg once daily (n = 31)”View highlighted excerpt for this quote“Lorundrostat, 100 mg once daily (n = 31)”View highlighted excerpt for this quote
Cohort 2, placebo“Placebo (n = 6)”View highlighted excerpt for this quote“Placebo (n = 6)”View highlighted excerpt for this quote
Description of analysis sets
Results
Participant disposition
Registered participant flow by group
DispositionPlacebo, Part 112.5 mg BID, Part 125 mg BID, Part 112.5 mg QD, Part 150 mg QD, Part 1100 mg QD, Part 1Placebo, Part 2100 mg QD, Part 2
Started“30”“22”“30”“23”“28”“30”“6”“31”
Completed“29”“18”“28”“18”“26”“27”“6”“30”
Not completed“1”“4”“2”“5”“2”“3”“0”“1”
Adverse event“0”“0”“0”“1”“0”“0”“0”“0”
Lost to follow-up“0”“1”“1”“2”“0”“1”“0”“0”
Not specified by investigator“0”“3”“0”“0”“1”“0”“0”“0”
Protocol violation“1”“0”“1”“1”“0”“1”“0”“0”
Withdrawal by subject“0”“0”“0”“1”“1”“1”“0”“1”
Baseline characteristics
Baseline characteristics by group
CharacteristicCohort 1, 100 mg QD (n = 30)Cohort 1, 50 mg QD (n = 28)Cohort 1, 25 mg BID (n = 30)Cohort 1, 12.5 mg BID (n = 22)Cohort 1, 12.5 mg QD (n = 23)Cohort 1, placebo (n = 30)Cohort 2, 100 mg QD (n = 31)Cohort 2, placebo (n = 6)
Age, mean (SD), y“68.7 (8.9)”View highlighted excerpt for this quote“64.7 (9.5)”View highlighted excerpt for this quote“64.8 (9.7)”View highlighted excerpt for this quote“68.1 (10.1)”View highlighted excerpt for this quote“65.2 (11.3)”View highlighted excerpt for this quote“62.6 (10.7)”View highlighted excerpt for this quote“66.6 (10.6)”View highlighted excerpt for this quote“62.7 (12.3)”View highlighted excerpt for this quote
Female, No. (%)“18 (60.0)”View highlighted excerpt for this quote“15 (53.6)”View highlighted excerpt for this quote“19 (63.3)”View highlighted excerpt for this quote“14 (63.6)”View highlighted excerpt for this quote“12 (52.2)”View highlighted excerpt for this quote“17 (56.7)”View highlighted excerpt for this quote“21 (67.7)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote
Black or African American, No. (%)“15 (50.0)”View highlighted excerpt for this quote“8 (28.6)”View highlighted excerpt for this quote“7 (23.3)”View highlighted excerpt for this quote“7 (31.8)”View highlighted excerpt for this quote“11 (47.8)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“6 (19.4)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote
White, No. (%)“14 (46.7)”View highlighted excerpt for this quote“19 (67.9)”View highlighted excerpt for this quote“23 (76.7)”View highlighted excerpt for this quote“15 (68.2)”View highlighted excerpt for this quote“11 (47.8)”View highlighted excerpt for this quote“13 (43.3)”View highlighted excerpt for this quote“25 (80.6)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote
Hispanic or Latino ethnicity, No. (%)“16 (53.3)”View highlighted excerpt for this quote“14 (50.0)”View highlighted excerpt for this quote“17 (56.7)”View highlighted excerpt for this quote“7 (31.8)”View highlighted excerpt for this quote“10 (43.5)”View highlighted excerpt for this quote“12 (40.0)”View highlighted excerpt for this quote“17 (54.8)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote
Body mass index, mean (SD)“30.4 (5.5)”View highlighted excerpt for this quote“32.0 (5.0)”View highlighted excerpt for this quote“30.6 (5.5)”View highlighted excerpt for this quote“32.0 (5.2)”View highlighted excerpt for this quote“30.6 (4.9)”View highlighted excerpt for this quote“31.9 (5.0)”View highlighted excerpt for this quote“30.5 (4.4)”View highlighted excerpt for this quote“32.0 (3.9)”View highlighted excerpt for this quote
Systolic AOBP at randomization, mean (SD), mm Hg“142.2 (13.4)”View highlighted excerpt for this quote“140.0 (12.1)”View highlighted excerpt for this quote“142.8 (13.1)”View highlighted excerpt for this quote“142.6 (13.3)”View highlighted excerpt for this quote“142.9 (13.7)”View highlighted excerpt for this quote“142.9 (10.7)”View highlighted excerpt for this quote“139.8 (9.1)”View highlighted excerpt for this quote“135.3 (5.5)”View highlighted excerpt for this quote
Diastolic AOBP at randomization, mean (SD), mm Hg“78.5 (10.0)”View highlighted excerpt for this quote“84.7 (7.0)”View highlighted excerpt for this quote“80.1 (9.3)”View highlighted excerpt for this quote“81.6 (9.4)”View highlighted excerpt for this quote“80.3 (12.0)”View highlighted excerpt for this quote“83.8 (9.5)”View highlighted excerpt for this quote“78.6 (10.0)”View highlighted excerpt for this quote“81.5 (7.9)”View highlighted excerpt for this quote
eGFR, mean (SD), mL/min/1.73 m2“77.4 (14.0)”View highlighted excerpt for this quote“77.2 (14.1)”View highlighted excerpt for this quote“80.9 (12.4)”View highlighted excerpt for this quote“81.7 (16.3)”View highlighted excerpt for this quote“77.9 (18.7)”View highlighted excerpt for this quote“81.6 (17.3)”View highlighted excerpt for this quote“79.9 (13.1)”View highlighted excerpt for this quote“83.9 (18.6)”View highlighted excerpt for this quote
Diabetes, No. (%)“8 (26.7)”View highlighted excerpt for this quote“8 (28.6)”View highlighted excerpt for this quote“11 (36.7)”View highlighted excerpt for this quote“9 (40.9)”View highlighted excerpt for this quote“11 (47.8)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“16 (51.6)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote
Heart failure, No. (%)“1 (3.3)”View highlighted excerpt for this quote“1 (3.6)”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“1 (4.5)”View highlighted excerpt for this quote“1 (4.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
2 background BP medications, No. (%)“14 (46.7)”View highlighted excerpt for this quote“20 (71.4)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“7 (31.8)”View highlighted excerpt for this quote“14 (60.9)”View highlighted excerpt for this quote“17 (56.7)”View highlighted excerpt for this quote“20 (64.5)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote
3 or more background BP medications, No. (%)“16 (53.3)”View highlighted excerpt for this quote“8 (28.6)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“15 (68.2)”View highlighted excerpt for this quote“9 (39.1)”View highlighted excerpt for this quote“13 (43.3)”View highlighted excerpt for this quote“11 (35.5)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote
Thiazide-type diuretic use, No. (%)“17 (56.7)”View highlighted excerpt for this quote“16 (57.1)”View highlighted excerpt for this quote“18 (60.0)”View highlighted excerpt for this quote“13 (59.1)”View highlighted excerpt for this quote“12 (52.2)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“19 (61.3)”View highlighted excerpt for this quote“5 (83.3)”View highlighted excerpt for this quote
ACE inhibitor or ARB use, No. (%)“23 (76.7)”View highlighted excerpt for this quote“20 (71.4)”View highlighted excerpt for this quote“27 (90.0)”View highlighted excerpt for this quote“17 (77.3)”View highlighted excerpt for this quote“18 (78.3)”View highlighted excerpt for this quote“22 (73.3)”View highlighted excerpt for this quote“30 (96.8)”View highlighted excerpt for this quote“5 (83.3)”View highlighted excerpt for this quote
Registered age distribution and region of enrollment
CharacteristicTotal (200 participants)
Age younger than 65 years“83”
Age 65 to 79 years“104”
Age 80 years or older“13”
Enrolled in the United States“200”
Body mass index, mean (SD), kg/m^2“31.1(5.0)”
Seated automated office systolic blood pressure, mean (SD), mmHg“141.6(12.0)”
Efficacy results
Primary end point: automated office systolic blood pressure at week 8
MeasureCohort 1, 100 mg QD (n = 25)Cohort 1, 50 mg QD (n = 28)Cohort 1, 25 mg BID (n = 28)Cohort 1, 12.5 mg BID (n = 19)Cohort 1, 12.5 mg QD (n = 19)Cohort 1, placebo (n = 29)Cohort 2, 100 mg QD (n = 31)Cohort 2, placebo (n = 6)
Baseline SBP, mean (SD), mm Hg“143.8 (12.0)”View highlighted excerpt for this quote“141.8 (10.9)”View highlighted excerpt for this quote“140.9 (9.6)”View highlighted excerpt for this quote“144.6 (10.5)”View highlighted excerpt for this quote“147.1 (11.6)”View highlighted excerpt for this quote“142.7 (10.2)”View highlighted excerpt for this quote“140.4 (8.6)”View highlighted excerpt for this quote“132.9 (8.4)”View highlighted excerpt for this quote
Week 8 SBP, mean (SD), mm Hg“131.3 (14.1)”View highlighted excerpt for this quote“128.6 (13.7)”View highlighted excerpt for this quote“131.3 (16.6)”View highlighted excerpt for this quote“131.9 (12.9)”View highlighted excerpt for this quote“140.8 (22.0)”View highlighted excerpt for this quote“139.1 (14.2)”View highlighted excerpt for this quote“129.3 (15.4)”View highlighted excerpt for this quote“128.3 (18.9)”View highlighted excerpt for this quote
Change in SBP, least-squares mean (SE), mm Hg“−11.9 (2.8)”View highlighted excerpt for this quote“−13.7 (2.7)”View highlighted excerpt for this quote“−11.1 (2.7)”View highlighted excerpt for this quote“−11.3 (3.2)”View highlighted excerpt for this quote“−5.6 (3.2)”View highlighted excerpt for this quote“−4.1 (2.6)”View highlighted excerpt for this quote“−11.4 (2.5)”View highlighted excerpt for this quoteNot reported
Difference from placebo, least-squares mean (90% CI), mm Hg“−7.8 (−14.1 to −1.5)”View highlighted excerpt for this quote“−9.6 (−15.8 to −3.4)”View highlighted excerpt for this quote“−7.0 (−13.1 to −0.8)”View highlighted excerpt for this quote“−7.2 (−14.0 to −0.4)”View highlighted excerpt for this quote“−1.5 (−8.3 to 5.3)”View highlighted excerpt for this quoteNot applicableNot reportedNot applicable
P value“.04”View highlighted excerpt for this quote“.01”View highlighted excerpt for this quote“.06”View highlighted excerpt for this quote“.08”View highlighted excerpt for this quote“.71”View highlighted excerpt for this quoteNot applicableNot reportedNot applicable
Secondary end point: automated office diastolic blood pressure at week 8
MeasureCohort 1, 100 mg QD (n = 25)Cohort 1, 50 mg QD (n = 28)Cohort 1, 25 mg BID (n = 28)Cohort 1, 12.5 mg BID (n = 19)Cohort 1, 12.5 mg QD (n = 19)Cohort 1, placebo (n = 29)Cohort 2, 100 mg QD (n = 31)Cohort 2, placebo (n = 6)
Baseline DBP, mean (SD), mm Hg“78.9 (9.6)”View highlighted excerpt for this quote“84.9 (6.4)”View highlighted excerpt for this quote“78.9 (8.0)”View highlighted excerpt for this quote“81.6 (7.6)”View highlighted excerpt for this quote“82.4 (10.7)”View highlighted excerpt for this quote“83.4 (8.8)”View highlighted excerpt for this quote“78.1 (7.6)”View highlighted excerpt for this quote“78.3 (7.6)”View highlighted excerpt for this quote
Week 8 DBP, mean (SD), mm Hg“73.0 (9.4)”View highlighted excerpt for this quote“76.8 (9.8)”View highlighted excerpt for this quote“75.4 (13.1)”View highlighted excerpt for this quote“75.2 (10.1)”View highlighted excerpt for this quote“81.4 (17.2)”View highlighted excerpt for this quote“81.3 (9.4)”View highlighted excerpt for this quote“72.2 (8.4)”View highlighted excerpt for this quote“76.2 (11.0)”View highlighted excerpt for this quote
Change in DBP, least-squares mean (SE), mm Hg“−5.8 (1.8)”View highlighted excerpt for this quote“−7.1 (1.7)”View highlighted excerpt for this quote“−4.1 (1.7)”View highlighted excerpt for this quote“−5.5 (2.0)”View highlighted excerpt for this quote“−3.8 (2.0)”View highlighted excerpt for this quote“−1.6 (1.7)”View highlighted excerpt for this quote“−5.6 (1.4)”View highlighted excerpt for this quoteNot reported
Difference from placebo, least-squares mean (90% CI), mm Hg“−4.1 (−8.1 to −0.1)”View highlighted excerpt for this quote“−5.5 (−9.4 to −1.5)”View highlighted excerpt for this quote“−2.5 (−6.4 to 1.4)”View highlighted excerpt for this quote“−3.8 (−8.2 to 0.5)”View highlighted excerpt for this quote“−2.1 (−6.5 to 2.2)”View highlighted excerpt for this quoteNot applicableNot reportedNot applicable
P value“.09”View highlighted excerpt for this quote“.02”View highlighted excerpt for this quote“.30”View highlighted excerpt for this quote“.14”View highlighted excerpt for this quote“.42”View highlighted excerpt for this quoteNot applicableNot reportedNot applicable
Secondary end point: ambulatory 24-hour blood pressure
MeasurePlacebo, Part 112.5 mg BID, Part 125 mg BID, Part 112.5 mg QD, Part 150 mg QD, Part 1100 mg QD, Part 1Placebo, Part 2100 mg QD, Part 2
Participants analyzed“26”“16”“26”“15”“28”“24”“0”“27”
Change in 24-hour mean SBP, least squares mean (SE), mmHg“-1.01(2.38)”“-5.78(3.03)”“-9.05(2.38)”“-2.51(3.15)”“-4.86(2.34)”“-6.34(2.5)”Not reported“-1.02(2.64)”
Change in 24-hour mean DBP, least squares mean (SE), mmHg“-0.90(1.46)”“-5.14(1.85)”“-6.03(1.45)”“-2.34(1.91)”“-3.64(1.40)”“-6.14(1.51)”Not reported“-0.07(1.69)”
Secondary end point: blood pressure below 130/80 mm Hg at week 8
MeasurePlacebo, Part 112.5 mg BID, Part 125 mg BID, Part 112.5 mg QD, Part 150 mg QD, Part 1100 mg QD, Part 1Placebo, Part 2100 mg QD, Part 2
Participants analyzed“30”“22”“30”“23”“28”“30”“6”“31”
Participants with blood pressure ≤ 130/80 mmHg at week 8“7”“7”“13”“6”“12”“9”“3”“17”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events and serum potassium changes by group
MeasureCohort 1, 100 mg QD (n = 30)Cohort 1, 50 mg QD (n = 28)Cohort 1, 25 mg BID (n = 30)Cohort 1, 12.5 mg BID (n = 22)Cohort 1, 12.5 mg QD (n = 23)Cohort 1, placebo (n = 30)Cohort 2, 100 mg QD (n = 31)Cohort 2, placebo (n = 6)
Any serious adverse event, No. (%)“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (9)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Any adverse event, No. (%)“17 (57)”View highlighted excerpt for this quote“12 (43)”View highlighted excerpt for this quote“20 (67)”View highlighted excerpt for this quote“13 (59)”View highlighted excerpt for this quote“16 (70)”View highlighted excerpt for this quote“12 (40)”View highlighted excerpt for this quote“19 (61)”View highlighted excerpt for this quote“1 (17)”View highlighted excerpt for this quote
Hypotension, No. (%)“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Change from baseline in serum potassium, mean (SD), mmol/L“0.29 (0.59)”View highlighted excerpt for this quote“0.25 (0.36)”View highlighted excerpt for this quote“0.34 (0.46)”View highlighted excerpt for this quote“0.32 (0.53)”View highlighted excerpt for this quote“0.31 (0.44)”View highlighted excerpt for this quote“0.03 (0.37)”View highlighted excerpt for this quote“0.21 (0.54)”View highlighted excerpt for this quote“−0.05 (0.28)”View highlighted excerpt for this quote
Serum potassium 5.6-6.0 mmol/L, No. (%)“5 (16)”View highlighted excerpt for this quote“1 (4)”View highlighted excerpt for this quote“2 (7)”View highlighted excerpt for this quote“2 (9)”View highlighted excerpt for this quote“3 (13)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Serum potassium 6.1-6.5 mmol/L, No. (%)“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“1 (5)”View highlighted excerpt for this quote“1 (4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Serum potassium >6.5 mmol/L, No. (%)“1 (3)”View highlighted excerpt for this quote“1 (4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Registered serious and other adverse events by group
Adverse event, affected / at risk (%)Placebo, Part 112.5 mg BID, Part 125 mg BID, Part 112.5 mg QD, Part 150 mg QD, Part 1100 mg QD, Part 1Placebo, Part 2100 mg QD, Part 2
All-cause mortality“0/30 (0.00%)”“0/22 (0.00%)”“0/30 (0.00%)”“0/23 (0.00%)”“0/28 (0.00%)”“0/30 (0.00%)”“0/6 (0.00%)”“0/31 (0.00%)”
Serious adverse events, total“0/30 (0.00%)”“0/22 (0.00%)”“0/30 (0.00%)”“2/23 (8.70%)”“0/28 (0.00%)”“0/30 (0.00%)”“0/6 (0.00%)”“1/31 (3.23%)”
Other adverse events, total“7/30 (23.33%)”“13/22 (59.09%)”“18/30 (60.00%)”“16/23 (69.57%)”“10/28 (35.71%)”“16/30 (53.33%)”“1/6 (16.67%)”“19/31 (61.29%)”
Hyperkalemia“1/30 (3.33%)”“5/22 (22.73%)”“9/30 (30.00%)”“6/23 (26.09%)”“3/28 (10.71%)”“8/30 (26.67%)”“0/6 (0.00%)”“8/31 (25.81%)”
Glomerular filtration rate decreased“1/30 (3.33%)”“3/22 (13.64%)”“0/30 (0.00%)”“1/23 (4.35%)”“0/28 (0.00%)”“5/30 (16.67%)”“0/6 (0.00%)”“1/31 (3.23%)”
Blood creatinine increased“0/30 (0.00%)”“0/22 (0.00%)”“0/30 (0.00%)”“0/23 (0.00%)”“0/28 (0.00%)”“3/30 (10.00%)”“0/6 (0.00%)”“1/31 (3.23%)”
Urinary tract infection“0/30 (0.00%)”“0/22 (0.00%)”“3/30 (10.00%)”“1/23 (4.35%)”“2/28 (7.14%)”“1/30 (3.33%)”“0/6 (0.00%)”“2/31 (6.45%)”
Hypotension“0/30 (0.00%)”“1/22 (4.55%)”“0/30 (0.00%)”“0/23 (0.00%)”“0/28 (0.00%)”“1/30 (3.33%)”“0/6 (0.00%)”“1/31 (3.23%)”
Orthostatic hypotension“0/30 (0.00%)”“1/22 (4.55%)”“0/30 (0.00%)”“2/23 (8.70%)”“0/28 (0.00%)”“0/30 (0.00%)”“0/6 (0.00%)”“0/31 (0.00%)”
Hypertension“0/30 (0.00%)”“0/22 (0.00%)”“1/30 (3.33%)”“2/23 (8.70%)”“2/28 (7.14%)”“0/30 (0.00%)”“0/6 (0.00%)”“0/31 (0.00%)”
Cortisol decreased“1/30 (3.33%)”“2/22 (9.09%)”“1/30 (3.33%)”“0/23 (0.00%)”“0/28 (0.00%)”“0/30 (0.00%)”“0/6 (0.00%)”“0/31 (0.00%)”
Study limitations
Summary

Target-HTN was a phase 2, dose-ranging trial that randomized 200 participants at sites in the United States to five lorundrostat regimens or placebo for 8 weeks, with no adjustment for multiplicity and with treatment differences reported as 90% confidence intervals. In cohort 1, the primary analysis included 19 to 29 participants per group, and the authors state that “each studied dose had a limited sample size”. Randomization to the 12.5 mg once-daily and 12.5 mg twice-daily groups stopped after the January 2022 interim analysis, and two interim analyses were performed in total. Cohort 1 enrolled only participants with suppressed renin; cohort 2 (37 participants, 6 receiving placebo) was exploratory, with no formal statistical testing against placebo. Sustained hypertension was not confirmed by 24-hour ambulatory monitoring before randomization, which the authors associate with “a prominent white-coat effect” in the 50 mg once-daily group. Participants with an eGFR below 60 mL/min/1.73 m2, or with serum potassium above 5.2 mmol/L (cohort 1) or 4.8 mmol/L (cohort 2), were excluded. The registered results define the proportion at goal as blood pressure of 130/80 mmHg or lower at week 8, while the publication describes it as below 130/80 mm Hg at week 7 or 8. The trial protocol was designed by the sponsor, Mineralys Therapeutics, which also provided input on the manuscript.

Explore-CKD

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Crossover Assignment”
Phase“Phase 2”
Enrollment (actual)“60”
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the posted results
AnalysisPlaceboLorundrostat
Primary outcome, overall number of participants analyzed“58”“58”
All-cause mortality, affected / at risk (%)“0/57 (0.00%)”“0/58 (0.00%)”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MilestoneCohort 1 (lorundrostat, then placebo)Cohort 2 (placebo, then lorundrostat)
Started“30”“29”
Completed“29”“28”
Not completed“1”“1”
Reason not completed: physician decision“1”“1”
Baseline characteristics
Baseline characteristics table (N = 59)
CharacteristicValue
Age, years, mean ± SD“64.6 ± 10.14”
Age 75 years or older, n (%)“13 (22.0)”
Male, n (%)“41 (69.5)”
Female, n (%)“18 (30.5)”
White, n (%)“39 (66.1)”
Black or African American, n (%)“10 (16.9)”
Hispanic or Latino, n (%)“25 (42.4)”
Body mass index, kg/m2, mean ± SD“33.1 ± 7.10”
Seated automated office systolic blood pressure, mm Hg, mean ± SD“148.9 ± 10.37”
Seated automated office diastolic blood pressure, mm Hg, mean ± SD“82.0 ± 10.49”
eGFR (cystatin C), ml/min per 1.73 m2, mean ± SD“43.0 ± 14.97”
eGFR (creatinine), ml/min per 1.73 m2, mean ± SD“54.6 ± 21.08”
UACR (24 hr), mg/g, geometric mean ± SD“559 ± 2.55”
Two or fewer antihypertensive medications, n (%)“21 (35.6)”
Three or more antihypertensive medications, n (%)“38 (64.4)”
β-Blockers, n (%)“28 (47.5)”
Selective calcium-channel blockers with mainly vascular effects, n (%)“30 (50.8)”
Type 2 diabetes mellitus, n (%)“45 (76.3)”
SGLT2i-naive at screening, n (%)“26 (44.1)”
Baseline systolic blood pressure by sequence in the posted results
GroupSeated automated office systolic blood pressure, mmHg, mean (SD)
Cohort 1 (lorundrostat, then placebo)“147.008(9.8704)”
Cohort 2 (placebo, then lorundrostat)“150.802(10.6962)”
Total“148.873(10.3731)”
Efficacy results
Primary outcome in the posted results
MeasurePlaceboLorundrostat
Least squares mean change from baseline, mmHg“-1.755”“-9.253”
90% confidence interval“(-4.966 to 1.455)”“(-12.453 to -6.053)”
Topline results table in the sponsor release
MeasurePlaceboLorundrostat 25 mgPlacebo-adjusted
Change in systolic BP (mmHg), primary endpoint“-1.76”“-9.25”“-7.5 (p=0.0024)”
Change in spot UACR (mg/g)“-6.60%”“-30.51%”“-25.60% (p=0.0015)”
Change in eGFR, cystatin C (mL/min/1.73m2)“-2.20%”“-6.78%”“-4.58% (p=0.0362)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Overview of treatment-emergent adverse events, n (%) and number of events
EventPlacebo (n = 57)Lorundrostat (n = 58)
TEAEs“19 (33.3) [36]”“29 (50.0) [54]”
Treatment-related TEAEs“8 (14.0) [9]”“16 (27.6) [24]”
Serious adverse events“0 (0.0) [0]”“2 (3.4) [4]”
Adverse events of special interest“1 (1.8) [1]”“10 (17.2) [13]”
TEAEs leading to discontinuation of the trial drug“1 (1.8) [1]”“2 (3.4) [3]”
TEAEs leading to dose modification of the trial drug“4 (7.0) [4]”“12 (20.7) [15]”
Death“0 (0.0) [0]”“0 (0.0) [0]”
Participants with at least 1 confirmed elevated potassium value, n (%)
Prespecified levelPlacebo (n = 57)Lorundrostat (n = 58)
Level 1: >5.5–6.0 mmol/l“1 (1.8)”“4 (6.9)”
Level 2: >6.0–6.5 mmol/l“0 (0.0)”“2 (3.4)”
Level 3: >6.5 mmol/l“0 (0.0)”“1 (1.7)”
Serious adverse events in the posted results
EventPlacebo, affected / at risk (%)Lorundrostat, affected / at risk (%)
Total“0/57 (0.00%)”“2/58 (3.45%)”
Influenza“0/57 (0.00%)”“1/58 (1.72%)”
Hyperkalaemia“0/57 (0.00%)”“1/58 (1.72%)”
Acute kidney injury“0/57 (0.00%)”“1/58 (1.72%)”
Other adverse events in the posted results (frequency threshold 2%)
EventPlacebo, affected / at risk (%)Lorundrostat, affected / at risk (%)
Total“18/57 (31.58%)”“29/58 (50.00%)”
Glomerular filtration rate decreased“2/57 (3.51%)”“6/58 (10.34%)”
Hyperkalaemia“2/57 (3.51%)”“9/58 (15.52%)”
Hyponatraemia“3/57 (5.26%)”“3/58 (5.17%)”
Hypotension“2/57 (3.51%)”“3/58 (5.17%)”
Orthostatic hypotension“1/57 (1.75%)”“2/58 (3.45%)”
Diastolic hypotension“1/57 (1.75%)”“2/58 (3.45%)”
Study limitations
Summary

Explore-CKD was a phase 2, two-period, two-sequence crossover trial with 4-week treatment periods separated by a 4-week washout. The publication reports 59 randomized participants at 42 sites in the United States; the registry lists an enrollment of 60 and 44 locations. One dose, lorundrostat 25 mg once daily, was studied. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure; albuminuria, proteinuria, and eGFR were exploratory endpoints, and no kidney or cardiovascular outcome was assessed. The investigators state that the 4-week treatment period “does not assess the durability of blood pressure lowering or longer-term safety and clinical outcomes” and that the findings “will require confirmation in a larger, longer-duration, parallel-arm trial”. Participants with serum potassium above 5.0 mmol/L at screening were excluded, which, with the short treatment duration, the investigators state “could underestimate hyperkalemia risk in routine clinical practice”; hyperkalemia was reported in 9 of 58 participants (15.5%) during lorundrostat treatment and 2 of 57 (3.5%) during placebo. The registry requires stable ACEi or ARB treatment for at least 2 months before screening, and the publication states at least 4 weeks. The trial was designed and funded by Mineralys Therapeutics, three authors are company employees, and no health-related quality of life or patient-reported outcome was reported.

Explore-OSA

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Crossover Assignment”
Phase“Phase 2”
Enrollment (actual)“48”
Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record

“Type 2 diabetes mellitus (T2DM) with a glycosylated hemoglobin (HbA1c) greater than (>) 9 percent (%) (>74.9 millimoles per mol [mmol/mol]) at the Screening Visit or history of diabetic ketoacidosis in the 6 months prior to the Screening Visit” (opens the source at this quote in a new tab)

“Participants on a glucagon-like peptide-1 (GLP-1) agonist.” (opens the source at this quote in a new tab)

“Have diagnosis of central or mixed sleep apnea with % of mixed or central apneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration” (opens the source at this quote in a new tab)

“Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia” (opens the source at this quote in a new tab)

“Use of bilevel positive airway pressure (BiPAP) therapy.” (opens the source at this quote in a new tab)

“eGFR less than (<) 45 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) at Screening using serum creatinine or cystatin-C” (opens the source at this quote in a new tab)

“Treatment with MRAs and/or epithelial sodium channel (ENaC) inhibitors within 1 month of the Screening Visit” (opens the source at this quote in a new tab)

“Unstable or currently symptomatic cardiovascular disease or hospitalization in the 6 months prior to Screening” (opens the source at this quote in a new tab)

“Previously diagnosed, recurrent orthostatic hypotension” (opens the source at this quote in a new tab)

“Current night-shift worker or anticipated to become a night-shift worker for 3 days continuously during the duration of the study.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics
Efficacy results
Summary: systolic blood pressure figures in the congress abstract and the company releases

The congress abstract reports the preplanned parallel-arm analysis of the first treatment period as a placebo-adjusted reduction in systolic blood pressure of 10.1 mmHg (P=0.0089). The NDA acceptance release and the AHA Hypertension 2026 release report within-group reductions of 11.1 mmHg with lorundrostat (p<0.0001) and 1.0 mmHg with placebo (p=NS) at week 4, and the NDA acceptance release attributes these figures to the pre-planned parallel arm analysis of the first period; the difference between the two within-group figures is 10.1 mmHg. The abstract and the NDA acceptance release both report a placebo-adjusted reduction of 6.2 mmHg (P<0.0003) in the crossover analysis of both treatment periods. The NDA acceptance release reports topline results.

Nighttime blood pressure

No evidence found.

Health-related quality of life and patient-reported outcomes
Epworth Sleepiness Scale and PROMIS sleep measures

No evidence found.

Safety results
Study limitations
Summary

Explore-OSA was a phase 2 crossover trial with two 4-week treatment periods separated by a 2-week washout; the registry lists 48 enrolled participants and the congress abstract describes 47. The primary endpoint, the placebo-adjusted change in apnea-hypopnea index at week 4, showed “no difference in AHI response between lorundrostat- and placebo-treated participants”. Office systolic blood pressure was a secondary endpoint, and the public results come from a congress abstract and company releases; no peer-reviewed publication or posted registry results were located, and the registry record shows a certification/extension submission dated 2026-08-17. The registry lists nighttime average systolic blood pressure as the first secondary outcome measure and also lists the Epworth Sleepiness Scale and two PROMIS sleep measures; no result for any of these was located in the public documents. The parallel-arm systolic blood pressure estimate uses the first treatment period alone, and the abstract and the company releases state it differently. The abstract states that “more than a third of participants were using PAP therapy”. Public safety reporting is limited to the absence of serious adverse events and of serum potassium values above 5.5 mmol/L. Eligibility excluded participants with eGFR below 45 mL/min/1.73 m2 and participants taking a GLP-1 agonist, and the registry lists 27 locations.

MT-4129-E01

Objective
Location and study date
Registered site, sponsor, and dates
FieldQuoted record
Location“Pharmaceutical Research Associates (PRA) Health Sciences”
Sponsor“Tanabe Pharma Corporation”
Other study ID number“MT-4129-E01”
Study start“2016-11”
Primary completion (actual)“2017-05”
Study completion (actual)“2017-05”
Study design
Registered design details
FieldQuoted record
Phase“Phase 1”
Allocation“Randomized”
Interventional model“Parallel Assignment”
Masking“Double”
Primary purpose“Other”
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics by dose group and part
Dose groupAge, years, mean (SD)Sex, n (%)Weight, kg, mean (SD)BMI (kg/m2), mean (SD)
Part 1, placebo (n = 16)“31.2 (12.9)”View highlighted excerpt for this quoteMale: “16 (100)”View highlighted excerpt for this quote“81.0 (7.8)”View highlighted excerpt for this quote“24.8 (2.1)”View highlighted excerpt for this quote
Part 1, 5 mg (n = 6)“29.0 (12.3)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“71.5 (5.3)”View highlighted excerpt for this quote“22.5 (1.8)”View highlighted excerpt for this quote
Part 1, 10 mg (n = 6)“31.7 (13.1)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“78.3 (12.4)”View highlighted excerpt for this quote“23.9 (3.7)”View highlighted excerpt for this quote
Part 1, 20 mg (n = 6)“27.5 (12.7)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“76.2 (7.6)”View highlighted excerpt for this quote“23.8 (2.8)”View highlighted excerpt for this quote
Part 1, 50 mg (n = 6)“28.2 (13.8)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“77.3 (7.2)”View highlighted excerpt for this quote“22.8 (2.2)”View highlighted excerpt for this quote
Part 1, 100 mg (n = 6)“27.8 (11.9)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“79.2 (8.7)”View highlighted excerpt for this quote“23.4 (1.9)”View highlighted excerpt for this quote
Part 1, 200 mg (n = 6)“28.3 (11.8)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“81.4 (12.3)”View highlighted excerpt for this quote“23.4 (2.3)”View highlighted excerpt for this quote
Part 1, 400 mg (n = 6)“28.5 (11.9)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“84.2 (6.8)”View highlighted excerpt for this quote“24.2 (2.8)”View highlighted excerpt for this quote
Part 1, 800 mg (n = 6)“33.2 (15.8)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“85.1 (9.9)”View highlighted excerpt for this quote“25.1 (2.9)”View highlighted excerpt for this quote
Part 2, placebo (n = 9)“29.3 (11.9)”View highlighted excerpt for this quoteMale: “9 (100)”View highlighted excerpt for this quote“78.5 (10.2)”View highlighted excerpt for this quote“23.6 (2.9)”View highlighted excerpt for this quote
Part 2, 40 mg (n = 9)“29.2 (10.4)”View highlighted excerpt for this quoteMale: “9 (100)”View highlighted excerpt for this quote“76.7 (8.6)”View highlighted excerpt for this quote“23.0 (2.3)”View highlighted excerpt for this quote
Part 2, 120 mg (n = 9)“26.3 (5.6)”View highlighted excerpt for this quoteMale: “9 (100)”View highlighted excerpt for this quote“77.8 (12.2)”View highlighted excerpt for this quote“22.8 (2.6)”View highlighted excerpt for this quote
Part 2, 360 mg (n = 9)“30.8 (11.6)”View highlighted excerpt for this quoteMale: “9 (100)”View highlighted excerpt for this quote“76.4 (11.7)”View highlighted excerpt for this quote“23.1 (4.1)”View highlighted excerpt for this quote
Part 3, placebo (n = 2)“23.0 (4.2)”View highlighted excerpt for this quoteFemale: “2 (100)”View highlighted excerpt for this quote“59.9 (8.9)”View highlighted excerpt for this quote“22.3 (3.3)”View highlighted excerpt for this quote
Part 3, 100 mg (n = 6)“25.5 (5.8)”View highlighted excerpt for this quoteFemale: “6 (100)”View highlighted excerpt for this quote“60.8 (4.7)”View highlighted excerpt for this quote“22.2 (1.7)”View highlighted excerpt for this quote
Part 4, placebo (n = 2)“72.5 (3.5)”View highlighted excerpt for this quoteMale: “2 (100)”View highlighted excerpt for this quote“77.2 (10.6)”View highlighted excerpt for this quote“27.9 (1.0)”View highlighted excerpt for this quote
Part 4, 100 mg (n = 6)“72.2 (4.1)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“77.9 (6.3)”View highlighted excerpt for this quote“25.1 (1.9)”View highlighted excerpt for this quote
Efficacy results
Plasma pharmacokinetic parameters by dose
Dose groupAUC, ng × h/mL, mean (SD)Cmax, ng/mL, mean (SD)t1/2, h, mean (SD)Tmax, h, median (minimum–maximum)
Single dose, 5 mg (AUC0–∞)“232 (25)”View highlighted excerpt for this quote“36.7 (6.7)”View highlighted excerpt for this quote“8.3 (0.7)”View highlighted excerpt for this quote“1.5 (1.0–3.0)”View highlighted excerpt for this quote
Single dose, 10 mg (AUC0–∞)“452 (46)”View highlighted excerpt for this quote“76.3 (20.4)”View highlighted excerpt for this quote“7.9 (0.9)”View highlighted excerpt for this quote“1.3 (1.0–1.5)”View highlighted excerpt for this quote
Single dose, 20 mg (AUC0–∞)“770 (183)”View highlighted excerpt for this quote“140.6 (76.1)”View highlighted excerpt for this quote“10.0 (1.9)”View highlighted excerpt for this quote“1.5 (1.0–3.0)”View highlighted excerpt for this quote
Single dose, 50 mg (AUC0–∞)“2157 (259)”View highlighted excerpt for this quote“572.8 (205.7)”View highlighted excerpt for this quote“9.1 (1.9)”View highlighted excerpt for this quote“1.0 (0.5–3.0)”View highlighted excerpt for this quote
Single dose, 100 mg (AUC0–∞)“5376 (495)”View highlighted excerpt for this quote“1211.0 (248.3)”View highlighted excerpt for this quote“10.0 (0.9)”View highlighted excerpt for this quote“1.5 (0.5–3.0)”View highlighted excerpt for this quote
Single dose, 200 mg (AUC0–∞)“10,660 (3483)”View highlighted excerpt for this quote“2847.5 (1015.2)”View highlighted excerpt for this quote“9.9 (3.6)”View highlighted excerpt for this quote“1.3 (1.0–3.0)”View highlighted excerpt for this quote
Single dose, 400 mg (AUC0–∞)“17,275 (2906)”View highlighted excerpt for this quote“4454.8 (862.4)”View highlighted excerpt for this quote“9.7 (2.3)”View highlighted excerpt for this quote“1.3 (0.5–3.0)”View highlighted excerpt for this quote
Single dose, 800 mg (AUC0–∞)“29,385 (3623)”View highlighted excerpt for this quote“7708.5 (1617.1)”View highlighted excerpt for this quote“10.5 (2.1)”View highlighted excerpt for this quote“1.5 (0.5–4.0)”View highlighted excerpt for this quote
Multiple dose, 40 mg, Day 7 (AUC0–24)“1795.0 (312.0)”View highlighted excerpt for this quote“365.1 (46.5)”View highlighted excerpt for this quote“9.1 (1.8)”View highlighted excerpt for this quote“2.0 (1.0–3.0)”View highlighted excerpt for this quote
Multiple dose, 120 mg, Day 7 (AUC0–24)“5816.0 (1315.0)”View highlighted excerpt for this quote“1038.7 (342.8)”View highlighted excerpt for this quote“11.9 (2.5)”View highlighted excerpt for this quote“1.5 (0.5–5.0)”View highlighted excerpt for this quote
Multiple dose, 360 mg, Day 7 (AUC0–24)“21825.0 (3955.0)”View highlighted excerpt for this quote“3812.1 (1282.3)”View highlighted excerpt for this quote“9.2 (2.5)”View highlighted excerpt for this quote“2.5 (1.0–4.0)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Treatment-related adverse events after single doses
Preferred term, n (%)Placebo (n = 16)5 mg (n = 6)10 mg (n = 6)20 mg (n = 6)50 mg (n = 6)100 mg (n = 6)200 mg (n = 6)400 mg (n = 6)800 mg (n = 6)
Headache“2 (12.5)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Somnolence“1 (6.3)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Dizziness“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Diarrhea“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Nausea“1 (6.3)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Asthenia“1 (6.3)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Treatment-related adverse events after multiple doses
Preferred term, n (%)Part 2, placebo (n = 9)Part 2, 40 mg (n = 9)Part 2, 120 mg (n = 9)Part 2, 360 mg (n = 9)
Headache“2 (22.2)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Dizziness postural“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Somnolence“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Dizziness“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Dysgeusia“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Sinus tachycardia“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Dyspnea“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Nausea“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Study limitations
Summary

MT-4129-E01 randomized 116 healthy white participants at one center in the Netherlands. Parts 1 and 2 enrolled men aged 18 to 55 years only, and the effects of sex and of age were each assessed in one cohort of 8 participants, 6 of whom received a single 100 mg dose. Multiple dosing lasted 7 days, so the study gives no information on longer treatment or on people with hypertension. Lorundrostat was given as a capsule whose exposure the authors state is about 50% of that of the tablet used in the phase 2 study, the comparison of fed and fasted pharmacokinetics was exploratory with no formal statistical comparison, and the formal tablet food effect study is described as “data on file”. The ClinicalTrials.gov record lists enrollment as estimated. The concentration-QTc analysis is reported in a congress poster by authors from Mineralys Therapeutics and Clario. The publication states that the studies it reports were funded by Mineralys Therapeutics, while the registry record names Tanabe Pharma Corporation as sponsor, and the authors include employees of Mitsubishi Tanabe Pharma Corporation, Mineralys Therapeutics, and ICON, the contract research organization that conducted the study.